Literature DB >> 2155973

The persistence of neutralizing antibodies after revaccination against smallpox.

B el-Ad1, Y Roth, A Winder, Z Tochner, T Lublin-Tennenbaum, E Katz, T Schwartz.   

Abstract

Persistence of neutralizing antibodies after revaccination against smallpox was studied. Single serum samples from 140 revaccinated donors were tested for neutralizing antibodies using the plaque reduction assay. The donors, aged 21-49 years at sampling, had been vaccinated in infancy and revaccinated at 8 and 18 years; they formed seven groups of 20 men each, revaccinated about 3, 5, 10, 15, 20, 25, and 30 years before sampling. The differences in mean titer among groups were insignificant (P greater than .01). The titer significantly decreased during the first 3 years after the revaccination but remained stable for at least 30 years thereafter (geometric mean titer, 10.5; 95% confidence interval, 6.8-16.4). The results suggest that there is probably no need for routine revaccinations beyond the primary and two revaccinations; nevertheless, persons at high risk should be revaccinated regardless of their vaccination status.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155973     DOI: 10.1093/infdis/161.3.446

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.

Authors:  Jesse D Troy; Heather R Hill; Marian G Ewell; Sharon E Frey
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.

Authors:  Shuji Hatakeyama; Kyoji Moriya; Masayuki Saijo; Yuji Morisawa; Ichiro Kurane; Kazuhiko Koike; Satoshi Kimura; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2005-04

Review 3.  Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

Authors:  Magdalini Moutaftsi; David C Tscharke; Kerrie Vaughan; David M Koelle; Lawrence Stern; Mauricio Calvo-Calle; Francis Ennis; Masanori Terajima; Gerd Sutter; Shane Crotty; Ingo Drexler; Genoveffa Franchini; Jon W Yewdell; Steven R Head; Janice Blum; Bjoern Peters; Alex Sette
Journal:  Future Microbiol       Date:  2010-02       Impact factor: 3.165

Review 4.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.

Authors:  Peter D Crompton; Marko Mircetic; Greta Weiss; Amy Baughman; Chiung-Yu Huang; David J Topham; John J Treanor; Iñaki Sanz; F Eun-Hyung Lee; Anna P Durbin; Kazutoyo Miura; David L Narum; Ruth D Ellis; Elissa Malkin; Gregory E D Mullen; Louis H Miller; Laura B Martin; Susan K Pierce
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

6.  Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection.

Authors:  Kevin L Karem; Mary Reynolds; Christine Hughes; Zach Braden; Pragati Nigam; Shane Crotty; John Glidewell; Rafi Ahmed; Rama Amara; Inger K Damon
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.

Authors:  Sook-Hyang Jeong; Ming Qiao; Michelina Nascimbeni; Zongyi Hu; Barbara Rehermann; Krishna Murthy; T Jake Liang
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Authors:  Richard Kennedy; V Shane Pankratz; Eric Swanson; David Watson; Hana Golding; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2009-06-17

9.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.

Authors:  Liyanage P Perera; Thomas A Waldmann; Joseph D Mosca; Nicole Baldwin; Jay A Berzofsky; SangKon Oh
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.